The newly developed urine test helps identify which prostate cancer patients need a biopsy and which can safely skip the ...

Telix to partner with companies developing advanced minimally invasive and image-guided ablative technologies for prostate cancer.Initial focus ...

SHREVEPORT, La. - Patients diagnosed with liver cancer in the ArkLaTex now have access to a new treatment option closer to ...

The non-invasive focused ultrasound system destroys liver tumours without surgery or radiation. Backed by Bezos Expeditions and valued at $2.25 billion, HistoSonics also submitted to the FDA for ...

The TFDA approval process included a detailed review of the company’s clinical and regulatory submission package and ...

Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets innovative interventional MRI (“iMRI”) procedures, is ...

Butterfly Medical, developer of a proprietary non-surgical solution for BPH (benign prostatic hyperplasia), today announced the successful completion of its Series C funding round, raising $21 million ...

Detailed price information for Profound Medical Corp (PROF-Q) from The Globe and Mail including charting and trades.

An innovative double-lung transplant helped a woman with terminal lung cancer breathe freely again, raising hope for advanced ...

A new study has highlighted a significant knowledge gap among patients about repeat radiotherapy (reirradiation) as a treatment option for recurrent prostate cancer ...

Detailed price information for Profound Medical Corp (PROF-Q) from The Globe and Mail including charting and trades.

The partners will incorporate Telix's PSMA-PET gallium 68-based imaging agents Gozellix and Illuccix with EDAP and Profound's technologies for minimally invasive treatment.